Tag:
Acorda Therapeutics
Latest Headlines
Latest Headlines
Acorda CEO Cohen throws his weight behind new biotech trailblazer
When I first met Acorda CEO Ron Cohen, the company's lead drug--Ampyra--was still in clinical development at its headquarters in Westchester County, NY. And even then he was quick to tout the area's
Acorda licenses rights to neurological candidate from Medtronic
Acorda Therapeutics has licensed worldwide development and commercialization rights to a proprietary magnesium formulation--referred to as AC105--from Medtronic. Acorda plans to study AC105 as an
Acorda snags Ph2 neurological trauma program in $35M deal
After hinting for some time that it's been shopping for a mid-stage product, Acorda this morning unveiled a $35 million licensing pact with Medtronic for a new therapy to treat neurological trauma
EU watchdogs reverse course on Fampyra
Reversing an earlier decision, European regulators have recommended approving Acorda Therapeutics' drug Fampyra, which is designed to improve the walking ability of patients with multiple sclerosis.
CHMP recommends approval of a host of new drugs
Some big news has come out of a key advisory committee for European drug approvals. In addition to backing approval of Merck's ( $MRK ) hepatitis C drug Victrelis ( boceprevir ), European Medicines
Chatter: Top biotech analyst selects list of likely takeover targets
With all the M&A activity--hostile as well as friendly--now underway in biotech, one of the hottest games in finance is predicting which developer will be the next to appear on the list of buyout
Which specialty drugmakers should Big Pharma buy?
Every so often, someone sets up a dartboard of likely targets for Big Pharma buyouts. This time, the target-setter is Barron's, and the focus is on companies with market values of $10 billion or
MS drugs get yeas, nays and price increases
Lots of news about the multiple sclerosis market today. Two companies raised prices, Novartis received good Gilenya news, while Merck KGaA and Biogen Idec/Acorda Therapeutics suffered setbacks
INCORRECT: Acorda deals MS med direct to patients
Editor's Note: Contrary to the Chicago Tribune article this piece was based on, Acorda has informed FiercePharma that the company is not selling directly to patients after all, but through specialty
CEOs turn out in NY to talk up new deals for a new year
NEW YORK - Biotech CEOs go to BIO's annual CEO & Investor confab at the Waldorf-Astoria to burnish the reputations of their companies in the heart of the world's financial center. And a lineup of
